Synavant gets takeover offer from Cegedim

Synavant, a USA-based global operator in customer relationship management and interactive marketing services for the biopharmaceutical industry, says that, on May 14, it received a proposal from Cegedim SA to acquire all of Synavant's outstanding common stock for $3.15 per share in cash.

On May 9, Synavant announced it had entered into a definitive agreement with Dendrite International for the latter to purchase all of the issued and outstanding Synavant stock at a price of $2.83 per share in cash.

In accordance with its merger agreement with Dendrite, the Synavant board of directors has authorized the company's management and advisors to enter into discussions and negotiations with Cegedim regarding its proposal. This authorization does not constitute approval or recommendation of Cegedim's bid by Synavant's board of directors nor has the board withheld, withdrawn, modified or changed its approval or its recommendation in favor of the Dendrite transaction, the company notes.